会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 8. 发明申请
    • METHODS OF SCREENING FOR COMPOUNDS THAT MODULATE TAFIa ACTIVITY, COMPOUNDS, AND METHODS OF USING THE COMPOUNDS
    • 筛选化合物的方法,该方法是调节TAFIA活性,化合物和使用该化合物的方法
    • WO2004019882A3
    • 2006-04-13
    • PCT/US0327070
    • 2003-08-29
    • AMERICAN DIAGNOSTICA INCQUEBEPHARMA RECH INC
    • GRENNFIELD ROBERT SAN SEONG SOO ATRIFONOV LATCHEZARVAUGEOIS JEANSLEMON CLAIRE
    • A61K31/60C12Q1/00C12Q1/56G01N33/573G01N33/68G01N33/86G01N33/94A61K38/28
    • C12Q1/37A61K31/60C12Q1/56G01N33/573G01N33/6893G01N33/86G01N33/9486G01N2500/00
    • Provided are methods of screening compounds for any aspirin-related activity other than TAFI inhibition, and also for non-inhibition of TAFI. Compounds identified by the screening methods can be used to treat, prevent or manage in a patient pain, fever, colon cancer, pancreatic cancer or an inflammatory, platelet aggregation, fibrinolytic or hemorrhagic disease or disorder. Also provided is a method of evaluating test compounds for TAFI inhibitory activity wherein the TAFI inhibitory activity of these test compounds is compared to the TAFI inhibitory activity of aspirin or its derivatives or metabolites. Further provided is a method of treating, preventing or managing in a patient, a hemorrhagic or thrombotic disease or disorder with high dose aspirin or aspirin derivatives or metabolites. Also contemplated is a method of treating, preventing or managing in a patient, pain, fever, colon cancer, pancreatic cancer or an inflammatory, platelet aggregation, fibrinolytic or hemorrhagic disease or disorder comprising administering aspirin or a derivative thereof or any other therapeutic having at least one desired therapeutic or prophylactic activity of aspirin to a patient in need thereof and administering to the patient a factor that promotes TAFIa activity,
    • 提供了筛选化合物除了TAFI抑制以外的任何阿司匹林相关活性的方法,以及用于非抑制TAFI的方法。 通过筛选方法鉴定的化合物可用于治疗,预防或控制患者疼痛,发烧,结肠癌,胰腺癌或炎症,血小板聚集,纤维蛋白溶解或出血性疾病或病症。 还提供了评价试验化合物对TAFI抑制活性的方法,其中将这些试验化合物的TAFI抑制活性与阿司匹林或其衍生物或代谢物的TAFI抑制活性进行比较。 还提供了一种治疗,预防或控制患者出血性或血栓性疾病或病症的方法,其中高剂量阿司匹林或阿司匹林衍生物或代谢物。 还考虑了治疗,预防或控制患者疼痛,发烧,结肠癌,胰腺癌或炎症,血小板聚集,纤维蛋白溶解或出血性疾病或病症的方法,包括给予阿司匹林或其衍生物或任何其它治疗剂 对有需要的患者的阿司匹林的至少一种期望的治疗或预防活性,并向患者施用促进TAFIa活性的因子,